Replies to post #586 on Clinuvel Pharmaceuticals (CLVLY)

[FarmaZutical]

I lean towards your second scenario. They probably offered the EMA data hoping that real life data would make up for trial data (that was not representative because of the difficulties getting patients to expose themselves to sunlight). Because of the extremely slow rollout partly due to the NICE fcukup they didn’t have enough patients online to offer the FDA sufficient data. I’m not really concerned about FDA approval. If I were, I would reduce my holding and I’m not. What I’m not happy about is the fact that they don’t have a professional PR person.